Molecular Genetic Testing for X-linked Mental Retardation Disorders

Benjamin Roa, Joanna Wiszniewska

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter discusses the four X-linked mental retardation disorders. Neurogenetic disorders display a variety of clinical phenotypes that are associated with mutations in specific genes. These genes often exhibit characteristic mutation profiles that illustrate different mutational mechanisms underlying human disease. These maternally inherited disorders include: fragile X syndrome (FXS) or FMR1-associated disorders, Rett syndrome or MECP2-associated disorders, CDKL5-associated disorders, and ARX-related disorders. Fragile X syndrome (FXS) is the most common inherited mental retardation disorder, occurring in about 1 in 3,500 males and approximately 1 in 7,000 females. Affected males are characterized by mild to moderate mental retardation, developmental delay, and behavioral problems. Physical features of FXS include a characteristic long face, prominent forehead, large ears, prominent jaw, and enlarged testicles or macro-orchidism. Affected females usually have mild mental retardation and a more variable phenotype, which renders them more difficult to diagnose clinically. The molecular basis of FXS is mutation of the FMR1gene. The FMR1mutation profile consists of unstable expansions of a CGG triplet repeat, which accounts for over 98% of mutations. Other mutations are rare and include point mutations in the RNA binding site, and intragenic or whole gene deletions involving FMR1. The major mutation affects a polymorphic CGG triplet repeat located at the 5' untranslated region (UTR) of FMR1. © 2010

Original languageEnglish (US)
Title of host publicationMolecular Diagnostics
PublisherElsevier Inc.
Pages167-176
Number of pages10
ISBN (Print)9780123694287
DOIs
StatePublished - Dec 1 2010
Externally publishedYes

Fingerprint

X-Linked Mental Retardation
Genetic Testing
Trinucleotide Repeats
Fragile X Syndrome
Molecular Biology
Genes
Mutation
Testing
Intellectual Disability
5' Untranslated Regions
Macros
Binding Sites
RNA
Rett Syndrome
Phenotype
Forehead
Gene Deletion
Jaw
Point Mutation
Mental Disorders

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Molecular Genetic Testing for X-linked Mental Retardation Disorders. / Roa, Benjamin; Wiszniewska, Joanna.

Molecular Diagnostics. Elsevier Inc., 2010. p. 167-176.

Research output: Chapter in Book/Report/Conference proceedingChapter

Roa, Benjamin ; Wiszniewska, Joanna. / Molecular Genetic Testing for X-linked Mental Retardation Disorders. Molecular Diagnostics. Elsevier Inc., 2010. pp. 167-176
@inbook{ec3527beb6e348729e607449ed8f336e,
title = "Molecular Genetic Testing for X-linked Mental Retardation Disorders",
abstract = "This chapter discusses the four X-linked mental retardation disorders. Neurogenetic disorders display a variety of clinical phenotypes that are associated with mutations in specific genes. These genes often exhibit characteristic mutation profiles that illustrate different mutational mechanisms underlying human disease. These maternally inherited disorders include: fragile X syndrome (FXS) or FMR1-associated disorders, Rett syndrome or MECP2-associated disorders, CDKL5-associated disorders, and ARX-related disorders. Fragile X syndrome (FXS) is the most common inherited mental retardation disorder, occurring in about 1 in 3,500 males and approximately 1 in 7,000 females. Affected males are characterized by mild to moderate mental retardation, developmental delay, and behavioral problems. Physical features of FXS include a characteristic long face, prominent forehead, large ears, prominent jaw, and enlarged testicles or macro-orchidism. Affected females usually have mild mental retardation and a more variable phenotype, which renders them more difficult to diagnose clinically. The molecular basis of FXS is mutation of the FMR1gene. The FMR1mutation profile consists of unstable expansions of a CGG triplet repeat, which accounts for over 98{\%} of mutations. Other mutations are rare and include point mutations in the RNA binding site, and intragenic or whole gene deletions involving FMR1. The major mutation affects a polymorphic CGG triplet repeat located at the 5' untranslated region (UTR) of FMR1. {\circledC} 2010",
author = "Benjamin Roa and Joanna Wiszniewska",
year = "2010",
month = "12",
day = "1",
doi = "10.1016/B978-0-12-369428-7.00015-X",
language = "English (US)",
isbn = "9780123694287",
pages = "167--176",
booktitle = "Molecular Diagnostics",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Molecular Genetic Testing for X-linked Mental Retardation Disorders

AU - Roa, Benjamin

AU - Wiszniewska, Joanna

PY - 2010/12/1

Y1 - 2010/12/1

N2 - This chapter discusses the four X-linked mental retardation disorders. Neurogenetic disorders display a variety of clinical phenotypes that are associated with mutations in specific genes. These genes often exhibit characteristic mutation profiles that illustrate different mutational mechanisms underlying human disease. These maternally inherited disorders include: fragile X syndrome (FXS) or FMR1-associated disorders, Rett syndrome or MECP2-associated disorders, CDKL5-associated disorders, and ARX-related disorders. Fragile X syndrome (FXS) is the most common inherited mental retardation disorder, occurring in about 1 in 3,500 males and approximately 1 in 7,000 females. Affected males are characterized by mild to moderate mental retardation, developmental delay, and behavioral problems. Physical features of FXS include a characteristic long face, prominent forehead, large ears, prominent jaw, and enlarged testicles or macro-orchidism. Affected females usually have mild mental retardation and a more variable phenotype, which renders them more difficult to diagnose clinically. The molecular basis of FXS is mutation of the FMR1gene. The FMR1mutation profile consists of unstable expansions of a CGG triplet repeat, which accounts for over 98% of mutations. Other mutations are rare and include point mutations in the RNA binding site, and intragenic or whole gene deletions involving FMR1. The major mutation affects a polymorphic CGG triplet repeat located at the 5' untranslated region (UTR) of FMR1. © 2010

AB - This chapter discusses the four X-linked mental retardation disorders. Neurogenetic disorders display a variety of clinical phenotypes that are associated with mutations in specific genes. These genes often exhibit characteristic mutation profiles that illustrate different mutational mechanisms underlying human disease. These maternally inherited disorders include: fragile X syndrome (FXS) or FMR1-associated disorders, Rett syndrome or MECP2-associated disorders, CDKL5-associated disorders, and ARX-related disorders. Fragile X syndrome (FXS) is the most common inherited mental retardation disorder, occurring in about 1 in 3,500 males and approximately 1 in 7,000 females. Affected males are characterized by mild to moderate mental retardation, developmental delay, and behavioral problems. Physical features of FXS include a characteristic long face, prominent forehead, large ears, prominent jaw, and enlarged testicles or macro-orchidism. Affected females usually have mild mental retardation and a more variable phenotype, which renders them more difficult to diagnose clinically. The molecular basis of FXS is mutation of the FMR1gene. The FMR1mutation profile consists of unstable expansions of a CGG triplet repeat, which accounts for over 98% of mutations. Other mutations are rare and include point mutations in the RNA binding site, and intragenic or whole gene deletions involving FMR1. The major mutation affects a polymorphic CGG triplet repeat located at the 5' untranslated region (UTR) of FMR1. © 2010

UR - http://www.scopus.com/inward/record.url?scp=84882526804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882526804&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-369428-7.00015-X

DO - 10.1016/B978-0-12-369428-7.00015-X

M3 - Chapter

AN - SCOPUS:84882526804

SN - 9780123694287

SP - 167

EP - 176

BT - Molecular Diagnostics

PB - Elsevier Inc.

ER -